Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)

Build status - In Progress

Recruiting

18 years - 55 years

All

Phase 3

10 participants needed

1 Location

Brief description of study

The research study is being conducted to learn whether an investigational drug called lebrikizumab could impact how effective certain vaccines may be and how effective and safe the study drug is in patients with moderate-to-severe AD compared with placebo. Research procedures include: Physical exam, Medical History, blood and urine tests, study medication and vaccines administered by injection, electronic diary completion and questionnaires.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Atopic Dermatitis,excema
Age: 18 years - 55 years
Gender: All

Male and Female, Age 15 - 55 Atopic Dermatitis ( excema)

Updated on 04 Aug 2024. Study ID: 845325

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center